InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.…
InterCure Regains Compliance with Nasdaq Minimum Bid Price Requirement
InterCure (NASDAQ: INCR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 285 employees.
The shares were at 3.240 USD on 20 November 2026, up 101.2% over 52 weeks.
Its market capitalisation is 42.03M USD.
InterCure reports return on equity of -9.0%, an operating margin of 0.0% and revenue up 23.9% year over year.
Its Piotroski F-score is 5 out of 9, an average reading of its financial health.